{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Neogene Therapeutics, Inc. (\"Neogene\"), headquartered in Santa Monica, CA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/10/26/2021-23289.html","cfr_references":[],"citation":"86 FR 59169","comment_url":null,"comments_close_on":"2021-11-10","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before November 10, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-23289","effective_on":null,"end_page":59174,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/10/26/2021-23289.xml","html_url":"https://www.federalregister.gov/documents/2021/10/26/2021-23289/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-23289?publication_date=2021-10-26","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-10-26/2021-23289/mods.xml","not_received_for_publication":null,"page_length":6,"page_views":{"count":593,"last_updated":"2026-09-23 06:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-10-26/pdf/2021-23289.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-23289.pdf?1635165929","publication_date":"2021-10-26","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/10/26/2021-23289.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T17:41:12Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":59169,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of CRISPR-Engineered T Cell Therapies for the Treatment of Cancer","toc_doc":"Development and Commercialization of CRISPR-Engineered T Cell Therapies for the Treatment of Cancer","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}